The national child measurement programme guidance for PCTs: 2007-08 school year

This guidance has been developed following wide consultation with primary care trusts (PCTs) and schools. It provides advice to PCTs on: arrangements for measuring the height and weight of primary and middle school children as part of the National Child Measurement Programme; and upload of this information to the Information Centre for health and social care (IC). refer to the resource

National Child Measurement Programme Guidance for 2007-08: Summary points

The guidance on the National Child Measurement Programme was published on 26 September 2007. This paper summarises the main points relevant to PCTs, SHAs and PHOs. The department of health website (see link at the end of the briefing) also includes specimen letters that can be customised for local use.

National Child Measurement Programme: detailed analysis of the 2007/08 dataset

The report provides analysis of PCT participation levels and investigates data quality issues in the collection of the 2007/08 NCMP dataset.

North West Child Height & Weight Measurement 2007

This analysis of child overweight and obesity data has been produced by the North West Public Health Observatory on behalf of PCTs in the region in order to look at inequalities across deprivation quintiles and to produce Local Authority District measures of child obesity.

National Child Measurement Programme. Detailed Analysis of the 2006/07 Dataset

The National Child Measurement Programme (NCMP) weighs and measures children in Reception (typically aged 4 - 5 years) and (aged 10 - years) annually. The report highlights the usefulness of the NCMP Dataset in furthering our understanding of underweight, overweight and obesity in children, as well as highlighting some areas where improvements can be made in the programme, or where further analysis and investigation is required. The purpose of this report is not to provide specific local results, but an understanding from national-level analysis that can be used to inform local uses and analysis of NCMP data.

National Child Measurement Programme: Detailed Analysis of the 2006/07 National Dataset

The National Obesity Observatory has produced a new report - National Child Measurement Programme: Detailed Analysis of the 2006/07 National Dataset. The report highlights the usefulness of the NCMP for advancing our understanding of underweight, overweight and obesity in children. The report looks at the effects of socio-demographic and other factors on the reported prevalence of childhood obesity. It also identifies areas where improvements can be made, and where further analysis and investigation are required.

Cervical screening: Frequently asked questions (FAQs)

Testing for high-risk human papillomavirus (HR-HPV) as triage and test of cure was introduced into the Northern Ireland Cervical Screening Programme on Monday 28 January 2013. This policy change will significantly alter the screening pathway for women with a mild dyskaryosis or borderline smear result. The link between HR-HPV infection and the development of cervical cancer has now been clearly established, with almost 100% of cervical cancers containing HPV DNA. Women with no evidence of HR-HPV infection are extremely unlikely to develop cervical cancer in the short to medium term. HPV triage is the process whereby HR-HPV testing is used to manage women with low grade cervical abnormalities. Only 15-20% of women with a borderline or mild smear result have a significant abnormality that needs treatment. HR-HPV testing is effective in identifying which women may need treatment and allows colposcopy resources to be allocated more effectively. The test of cure process is being introduced because it is now known that women with a normal or low grade smear test, and who are HR-HPV negative at six months after treatment, are at very low risk of residual disease. These women do not need to be recalled for another screening appointment for three years. The test of cure process means all post-treatment smears (at six months) that are reported as normal, borderline or mild dyskaryosis will be tested for HR-HPV. Those women who are HR-HPV positive will remain at colposcopy. HR-HPV negative women can be safely returned to recall in three years. It is estimated that the HR-HPV test of cure will allow approximately 80% of women who have been through treatment to avoid undergoing annual smear tests. These FAQs answer the most common and important queries in relation to HPV and the new screening process, and were distributed to all GPs in Northern Ireland. They can be downloaded as a PDF from this website.

Cervical screening programme: HPV triage and test of cure protocol

Testing for high-risk human papillomavirus (HR-HPV) as triage and test of cure was introduced into the Northern Ireland Cervical Screening Programme on Monday 28 January 2013. This policy change will significantly alter the screening pathway for women with a mild dyskaryosis or borderline smear result. The link between HR-HPV infection and the development of cervical cancer has now been clearly established, with almost 100% of cervical cancers containing HPV DNA. Women with no evidence of HR-HPV infection are extremely unlikely to develop cervical cancer in the short to medium term. HPV triage is the process whereby HR-HPV testing is used to manage women with low grade cervical abnormalities. Only 15-20% of women with a borderline or mild smear result have a significant abnormality that needs treatment. HR-HPV testing is effective in identifying which women may need treatment and allows colposcopy resources to be allocated more effectively.The test of cure process is being introduced because it is now known that women with a normal or low grade smear test, and who are HR-HPV negative at six months after treatment, are at very low risk of residual disease. These women do not need to be recalled for another screening appointment for three years.The test of cure process means all post-treatment smears (at six months) that are reported as normal, borderline or mild dyskaryosis will be tested for HR-HPV. Those women who are HR-HPV positive will remain at colposcopy. HR-HPV negative women can be safely returned to recall in three years. It is estimated that the HR-HPV test of cure will allow approximately 80% of women who have been through treatment to avoid undergoing annual smear tests. This flowchart poster outlines the new triage and test of cure process. It was distributed to all GPs in Northern Ireland and is available to download as a PDF from this website.�

Northern Ireland cervical screening programme: information for primary care and smear takers

From January 2011, the Northern Ireland cervical screening programme no longer invited women aged under 25 to attend for screening. In addition, the screening interval for women aged 25-49 was reduced to every three years.This�booklet describes the rationale for the change in policy so that primary care staff and smear takers can provide appropriate and accurate advice to patients.

Beating cervical cancer. The HPV vaccine - questions and answers for parents of girls in Year 9 (English and eight translations)

This leaflet provides more detailed information in a question and answer format about the HPV vaccine offered to girls in Year 9 which can help protect against cervical cancer.

Beating cervical cancer: information for girls in Year 9, aged 12-13 (English and eight translations)

This leaflet is distributed to girls in Year 9 and explains about the HPV vaccine, which can help protect against cervical cancer.

Cervical screening: your results explained (English and 11 translations)

Testing for high-risk human papillomavirus (HR-HPV) as triage and test of cure was introduced into the Northern Ireland Cervical Screening Programme on Monday 28 January 2013. This policy change will significantly alter the screening pathway for women with a mild dyskaryosis or borderline smear result.

Cervical screening: the colposcopy examination (English and 11 translations)

Testing for high-risk human papillomavirus (HR-HPV) as triage and test of cure was introduced into the Northern Ireland Cervical Screening Programme on Monday 28 January 2013. This policy change will significantly alter the screening pathway for women with a mild dyskaryosis or borderline smear result.

Cervical cancer: it's best to take the test (English and 11 translations)

Testing for high-risk human papillomavirus (HR-HPV) as triage and test of cure was introduced into the Northern Ireland Cervical Screening Programme on Monday 28 January 2013. This policy change will significantly alter the screening pathway for women with a mild dyskaryosis or borderline smear result.